More IDO Issues: NewLink Drops Pancreatic Cancer Indication For Indoximod

NewLink has scrapped plans to explore its IDO inhibitor in pancreatic cancer – more bad news for a drug class that has suffered several setbacks recently.

Juggling
NewLink juggles too many indoximod options; drops pancreatic cancer program • Source: Shutterstock

NewLink Genetics Corp. has “deprioritized” pancreatic cancer and will not proceed with a planned Phase II study testing its lead product indoximod with AstraZeneca PLC's Imfinzi (durvalumab), the company said during its first-quarter earnings announcement.

This follows on from news last month that NewLink had halted the Phase III Indigo301 study of indoximod in combination...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immuno-oncology

More from Anticancer